Page last updated: 2024-08-25

oxazolidin-2-one and Atheroma

oxazolidin-2-one has been researched along with Atheroma in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Arsenault, BJ; Brodeur, MR; Rhainds, D; Tardif, JC	1

Reviews

1 review(s) available for oxazolidin-2-one and Atheroma

Article	Year
An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels. Future cardiology, 2012, Volume: 8, Issue:4 Topics: Amides; Animals; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Clinical Trials, Phase II as Topic; Drug Therapy, Combination; Esters; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Metabolic Syndrome; Niacin; Oxazolidinones; Plaque, Atherosclerotic; Recurrence; Sulfhydryl Compounds	2012

Article

Year

An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels.

Future cardiology, 2012, Volume: 8, Issue:4

Topics: Amides; Animals; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Clinical Trials, Phase II as Topic; Drug Therapy, Combination; Esters; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Metabolic Syndrome; Niacin; Oxazolidinones; Plaque, Atherosclerotic; Recurrence; Sulfhydryl Compounds

2012